SCHEMBL10140470

SCHEMBL10140470

COc1c(-c2ccc(CO[Si](C)(C)C(C)(C)C)cc2)nn(C)c1C(C)=O

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 2/20 0.32
PREP P48147 1/20 0.31
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
MEN1 O00255 1/20 0.30
PKM P14618 1/20 0.30
MDM2 Q00987 1/20 0.30
KMT2A Q03164 1/20 0.30
USP14 P54578 1/20 0.30
MAPK1 P28482 1/20 0.30
CSF1R P07333 1/20 0.30
FGFR1 P11362 1/20 0.30
FLT1 P17948 1/20 0.30
KDR P35968 1/20 0.30
CSNK1A1 P48729 1/20 0.30
CDK8 P49336 1/20 0.30
GSK3A P49840 1/20 0.30
GSK3B P49841 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16258908 0.91 SMN1; SMN2 (0.36) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL16258907 0.79 HDAC1 (0.37)
SCHEMBL20307752 0.78 SMN1; SMN2 (0.33) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL10140694 0.76 MAPT (0.38) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL10140385 0.76 CSF1R (0.49) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL14648434 0.72 KMT2A (0.48) MAPTSMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL10140757 0.70 PDE10A (0.41) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL10140710 0.67 TP53 (0.46) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL18310146 0.67 DRD2 (0.41) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL10140393 0.67 TP53 (0.48) MAPTSMN1; SMN2ALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 KCNA3 1052/4885PREP 97/4885MAPT 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.